<DOC>
	<DOCNO>NCT00093639</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , everolimus , work different way stop cancer cell divide stop grow die . Imatinib mesylate may stop growth cancer cell block enzymes necessary growth . Combining everolimus imatinib mesylate may effective kill cancer cell become resistant imatinib mesylate . PURPOSE : This phase I/II trial study side effect best dose everolimus give together imatinib mesylate see well work treat patient chronic phase chronic myelogenous leukemia complete cytogenetic remission previous imatinib mesylate .</brief_summary>
	<brief_title>Everolimus Imatinib Mesylate Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not Complete Cytogenetic Remission After Previous Imatinib Mesylate</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety , tolerability , biological activity everolimus combine imatinib mesylate patient chronic phase chronic myelogenous leukemia complete cytogenetic remission prior imatinib mesylate . ( Phase I ) - Determine , preliminarily , clinical efficacy regimen , term 3-month improvement least one cytogenetic category duration cytogenetic improvement , patient . ( Phase II ) Secondary - Determine 6-month rate cytogenetic improvement patient treated regimen . - Determine rate confirm cytogenetic improvement patient treated regimen . - Determine rate duration major cytogenetic response patient treat regimen . - Determine rate kinetics molecular response patient treat regimen . - Correlate genetic variation drug metabolism gene , leukemia gene , drug target gene response patient treat regimen . - Determine pharmacokinetics regimen patient . - Determine whether mTOR pathway activity , determine molecular pathologic examination treatment regimen , predictive response patient . OUTLINE : This phase I , non-randomized , open-label , multicenter , dose-escalation study everolimus follow phase II study . Patients stratify accord baseline cytogenetic status ( Philadelphia chromosome-positive cell bone marrow ) ( &gt; 0 % ≤ 95 % v &gt; 95 % ) . - Phase I : Patients receive oral everolimus daily ( weekly ) oral imatinib mesylate daily begin day 1 . Treatment continue absence disease progression unacceptable toxicity . Cohorts 4-6 patient receive escalate dos everolimus maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive everolimus imatinib mesylate phase I MTD . Patients follow every 6 month . PROJECTED ACCRUAL : A total 4-98 patient ( 4-34 phase I 64 phase II [ 34 patient &gt; 0 % ≤ 95 % Philadelphia chromosome ( Ph ) -positive cell 30 patient &gt; 95 % Ph-positive cell ] ) accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm chronic myelogenous leukemia ( CML ) In chronic phase Philadelphia chromosome ( Ph ) positive No accelerate blastic phase Accelerated phase CML define ≥ 15 % &lt; 30 % blast peripheral blood bone marrow OR ≥ 30 % blast promyelocytes peripheral blood bone marrow provide &lt; 30 % blast present OR ≥ 20 % peripheral basophil OR platelet count &lt; 100,000/mm^3 , unrelated therapy No le 20 metaphase bone marrow sample No evidence complete cytogenetic response imatinib mesylate ( complete cytogenetic response define 0 % Phpositive cell bone marrow ) Receiving continuous imatinib mesylate therapy ≥ past 9 month Dosage ≥ 600 mg/day ≥ past 3 month Stable dose 600 mg/day ≥ past 4 week Achieved maintain hematological response imatinib mesylate define follow : WBC &lt; 20,000/mm^3 Basophils &lt; 20 % Less 5 % myelocyte metamyelocytes peripheral blood No blast promyelocytes peripheral blood No evidence diseaserelated symptom extramedullary disease , include enlarge spleen liver PATIENT CHARACTERISTICS : Age 18 Performance status WHO 02 Life expectancy Not specify Hematopoietic See Disease Characteristics Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Hepatic AST ALT &lt; 1.5 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 time ULN ( except patient Gilbert 's disease ) PTT &lt; 1.5 time ULN ( except patient oral anticoagulation therapy ) INR &lt; 1.5 time ULN ( except patient oral anticoagulation therapy ) Renal Creatinine &lt; 1.5 time ULN Cardiovascular No angina No New York Heart Association class III IV cardiac disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 3 month study participation HIV negative No history noncompliance medical regimens No hypercholesterolemia hypertriglyceridemia ( fast state ) ≥ grade 2 ( despite lipidlowering therapy ) No diabetes mellitus No thyroid dysfunction No neuropsychiatric disorder No infection No severe and/or uncontrolled medical condition would preclude study participation No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy No prior allogeneic , syngeneic , autologous bone marrow transplantation stem cell transplantation CML No concurrent prophylactic hematopoietic growth factor ( e.g. , filgrastim [ GCSF ] , sargramostim [ GMCSF ] , epoetin alfa ) Chemotherapy No prior chemotherapy regimen use transplantation Endocrine therapy Not specify Radiotherapy Not specify Surgery Recovered prior major surgery Other No prior sirolimus combination imatinib mesylate At least 4 week since prior investigational agent use combination imatinib mesylate recover No concurrent investigational therapy No concurrent anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
</DOC>